Idalopirdine-based combinatorial therapies of alzheimer's disease

一种组合物、阿坎酸的技术，应用在新的组合领域，能够解决没有教导idalopirdine显示出作用等问题，达到安全治疗的效果

Inactive Publication Date: 2020-04-21
PHARNEXT
View PDF27 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, US 9,144,558 does not teach that the combination of idalopirdine, baclofen and acamprosate can be effective at less than optimal doses of idalopirdine, let alone produce a synergistic effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Idalopirdine-based combinatorial therapies of alzheimer's disease
  • Idalopirdine-based combinatorial therapies of alzheimer's disease
  • Idalopirdine-based combinatorial therapies of alzheimer's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0170] A - Combination therapy of the invention prevents Aβ in vivo 25-42 Cognitive impairment due to toxicity

[0171] Peptide amyloid-beta 25-35 (Aβ 25-35 ) is the hydrophobic portion of the full-length amyloid peptide. Injection of this peptide into the ventricles of rodents is known to induce a progressive neurodegenerative process leading to cognitive deficits. This model is commonly used in disorders involving symptoms of cognitive impairment [49-53]. The results of this example demonstrate that the combination of idalopirdine (at a suboptimal dose), baclofen and acamprosate is not only effective but also acts synergistically to protect treated animals from neurodegeneration due to injection of toxic peptides process.

[0172] treatment solutions

[0173] Male Swiss mice were administered from day 0 to day 10:

[0174] - fake products (groups 1 and 2);

[0175] - Baclofen, acamprosate and idalopirdine at 0.480 mg / kg, 0.032 mg / kg and 4.5 mg / kg respectively (group ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to combinatorial therapies and methods for the treatment of Alzheimer's disease or an Alzheimer's disease related disorder based on idalopirdine, baclofen and acamprosate, wherein idalopirdine is provided as suboptimal doses.

Description

technical field [0001] The present invention relates to novel combinations and methods for the treatment of Alzheimer's disease and related diseases. More specifically, the present invention relates to novel combination treatments for Alzheimer's disease and related diseases based on idalopirdine, baclofen and acamprosate. Background technique [0002] Alzheimer's disease (AD) is a prototypical cortical dementia characterized by memory impairment accompanied by speech difficulties (language impairment in which speech and language comprehension are impaired), movement disorders (in the absence of motor or sensory impairment Inability to coordinate and execute certain voluntary movements and gestures) and cognitive impairment (inability to recognize objects, people, sounds, shapes, or smells), which can be attributed to the involvement of relevant areas of the cortex. Specific symptoms such as spastic paraplegia (weakness affecting the lower extremities) may also be involved ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/185A61K31/195A61K31/404A61P25/28
CPCA61K31/185A61K31/195A61K31/404A61P25/28A61K2300/00
Inventor D.科恩S.纳比罗赫金R.哈杰A.布鲁里奥
Owner PHARNEXT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap